Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

129 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
In vivo and in vitro evaluation of Gd-DTPA-polylysine as a macromolecular contrast agent for magnetic resonance imaging.
Schuhmann-Giampieri G, Schmitt-Willich H, Frenzel T, Press WR, Weinmann HJ. Schuhmann-Giampieri G, et al. Invest Radiol. 1991 Nov;26(11):969-74. doi: 10.1097/00004424-199111000-00008. Invest Radiol. 1991. PMID: 1743920
A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI.
Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H. Weinmann HJ, et al. Magn Reson Med. 1991 Dec;22(2):233-7; discussion 242. doi: 10.1002/mrm.1910220214. Magn Reson Med. 1991. PMID: 1812351
Characterization of a gadolinium-labeled cholesterol derivative as an organ-specific contrast agent for adrenal MR imaging.
Mühler A, Platzek J, Radüchel B, Frenzel T, Weinmann HJ. Mühler A, et al. J Magn Reson Imaging. 1995 Jan-Feb;5(1):7-10. doi: 10.1002/jmri.1880050104. J Magn Reson Imaging. 1995. PMID: 7696812
Gadolinium-DO3A-labeled cholesterol was synthesized and the relaxivities in water and blood plasma determined at 0.47 T and 40 degrees C. ...T1-weighted spin-echo images were acquired at 2 T before and after injection of 50 mumol/kg Gd-DO3A-cholesterol (n = 2) and G …
Gadolinium-DO3A-labeled cholesterol was synthesized and the relaxivities in water and blood plasma determined at 0.47 T and 40 degree …
Comparison of iopamidol and ioversol in vitro and in animal studies.
Krause W, Miyazawa T, Uchimoto R, Murayama C, Fritz-Zieroth B, Press WR, Frenzel T. Krause W, et al. Arzneimittelforschung. 1995 Feb;45(2):200-4. Arzneimittelforschung. 1995. PMID: 7710450
Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.
Hamm B, Staks T, Mühler A, Bollow M, Taupitz M, Frenzel T, Wolf KJ, Weinmann HJ, Lange L. Hamm B, et al. Radiology. 1995 Jun;195(3):785-92. doi: 10.1148/radiology.195.3.7754011. Radiology. 1995. PMID: 7754011 Clinical Trial.
Noninvasive in vivo pH measurements using a fluorinated pH probe and fluorine-19 magnetic resonance spectroscopy.
Frenzel T, Kossler S, Bauer H, Niedballa U, Weinmann HJ. Frenzel T, et al. Invest Radiol. 1994 Jun;29 Suppl 2:S220-2. doi: 10.1097/00004424-199406001-00073. Invest Radiol. 1994. PMID: 7928237 No abstract available.
Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers.
Staks T, Schuhmann-Giampieri G, Frenzel T, Weinmann HJ, Lange L, Platzek J. Staks T, et al. Invest Radiol. 1994 Jul;29(7):709-15. doi: 10.1097/00004424-199407000-00008. Invest Radiol. 1994. PMID: 7960618 Clinical Trial.
Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide.
Hamm B, Staks T, Taupitz M, Maibauer R, Speidel A, Huppertz A, Frenzel T, Lawaczeck R, Wolf KJ, Lange L. Hamm B, et al. J Magn Reson Imaging. 1994 Sep-Oct;4(5):659-68. doi: 10.1002/jmri.1880040508. J Magn Reson Imaging. 1994. PMID: 7981510 Clinical Trial.
MR imaging at 1.5 T was performed before and 8 hours to 14 days after fast intravenous injection (500 mumol Fe/min) of the SPIO (six subjects per dose). ...
MR imaging at 1.5 T was performed before and 8 hours to 14 days after fast intravenous injection (500 mumol Fe/min) of the SPIO (six …
129 results
Jump to page
Feedback